Overview

Treatment of Advanced Solid Tumor With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety of TSA-CTL in the treatment of the advanced melanoma. The secondary purpose of this study is to evaluate preliminarily the effect of TSA-CTL in the treatment of the advanced melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
BGI, China
Collaborator:
Sun Yat-sen University
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Vidarabine